Preventing driveline infection during left ventricular assist device support by the HeartMate 3: A survey-based study.


Journal

Artificial organs
ISSN: 1525-1594
Titre abrégé: Artif Organs
Pays: United States
ID NLM: 7802778

Informations de publication

Date de publication:
Jul 2022
Historique:
revised: 30 11 2021
received: 26 10 2021
accepted: 07 01 2022
pubmed: 28 1 2022
medline: 11 6 2022
entrez: 27 1 2022
Statut: ppublish

Résumé

Driveline infection (DLI) is a significant source of morbidity and mortality during left ventricular assist device (LVAD) support yet limited studies are available to describe the center-level prevalence, preventive practices, and their potential effectiveness. We surveyed LVAD centers in the United States to determine program burden and preventive practices for DLI during HeartMate (HM) 3 support. An online, anonymous, question-based survey was sent to expert providers at implanting centers. Only a single respondent completed the survey for each center. As an exploratory analysis, we compared specific DLI preventive practices between centers with low (≤10%) and high (>10%) reported prevalence of DLI. Seventy-eight centers responded to the survey (response rate: 50%). Respondents were comprised of 37 (47%) heart failure cardiologists, 27 (35%) LVAD coordinators, and 14 (18%) cardiothoracic surgeons. The prevalence of DLI during HM3 was reported as ≤10% by 27 (35%), 11%-25% by 36 (46%), and >25% by 16 (19%) centers. Thirteen (17%) centers had a body mass index threshold for device placement, 29 (37%) utilized a counter incision, 66 (81%) placed an anchor stitch, and 69 (88%) used an external device to stabilize the DL. Proportionally, more centers with a low DLI prevalence used a wound vacuum 6 (22%) versus 3 (6%, p = 0.03) than those with high DLI. Variation exists in reported prevalence and practices of preventing and managing driveline infections across centers during HM3 support. Further studies are warranted to develop and assess the effectiveness of standardized preventive strategies.

Identifiants

pubmed: 35083754
doi: 10.1111/aor.14187
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1409-1414

Subventions

Organisme : NIH HHS
ID : K23HL145140
Pays : United States
Organisme : National Institute of Health/National Heart, Lung, and Blood Institute
ID : K23HL145140
Organisme : National Center for Advancing Translational Science (NCATS) Clinical and Translational Science Award at Einstein-Montefiore
ID : UL1TR001073
Organisme : Abbott Inc.
Organisme : NIH HHS
ID : K23HL145140
Pays : United States

Informations de copyright

© 2022 International Center for Artificial Organs and Transplantation and Wiley Periodicals LLC.

Références

Molina EJ, Shah P, Kiernan MS, Cornwell WK III, Copeland H, Takeda K, et al. The Society of Thoracic Surgeons Intermacs 2020 annual report. Ann Thorac Surg. 2021;111:778-92.
Mehra MR, Uriel N, Naka Y, Cleveland JC Jr, Yuzefpolskaya M, Salerno CT, et al. A fully magnetically levitated left ventricular assist device. N Engl J Med. 2019;380:1618-27.
Shah P, Birk SE, Cooper LB, Psotka MA, Kirklin JK, Barnett SD, et al. Stroke and death risk in ventricular assist device patients varies by ISHLT infection category: an INTERMACS analysis. J Heart Lung Transplant. 2019;38:721-30.
Leuck A-M. Left ventricular assist device driveline infections: recent advances and future goals. J Thorac Dis. 2015;7:2151.
Wilcox JE, Cameron KA, Harap RS, Shanklin KL, Grady KL, Cohen ER, et al. Ventricular assist device driveline dressing change protocols: a need for standardization: a report from the SimVAD investigators. J Card Fail. 2019;25:695-7.
Maltais S, Kilic A, Nathan S, Keebler M, Emani S, Ransom J, et al. PREVENtion of HeartMate II pump thrombosis through clinical management: the PREVENT multi-center study. J Heart Lung Transplant. 2017;36:1-12.
Yarboro LT, Bergin JD, Kennedy JL, Ballew CC, Benton EM, Ailawadi G, et al. Technique for minimizing and treating driveline infections. Ann Cardiothorac Surg. 2014;3:557.
Cagliostro B, Levin AP, Fried J, Stewart S, Parkis G, Mody KP, et al. Continuous-flow left ventricular assist devices and usefulness of a standardized strategy to reduce drive-line infections. J Heart Lung Transplant. 2016;35:108-14.
Cirocchi R, Birindelli A, Biffl WL, Mutafchiyski V, Popivanov G, Chiara O, et al. What is the effectiveness of the negative pressure wound therapy (NPWT) in patients treated with open abdomen technique? A systematic review and meta-analysis. J Trauma Acute Care Surg. 2016;81:575-84.
Bernhardt AM, Schlöglhofer T, Lauenroth V, Mueller F, Mueller M, Schoede A, et al. Prevention and early treatment of driveline infections in ventricular assist device patients-the DESTINE staging proposal and the first standard of care protocol. J Crit Care. 2020;56:106-12.

Auteurs

Omar Saeed (O)

Department of Medicine (Cardiology), Montefiore Medical Center, Bronx, New York, USA.

Noah Moss (N)

Department of Medicine (Cardiology), Mount Sinai Medical Center, New York, New York, USA.

Bryan Barrus (B)

Department of Cardiothoracic Surgery, University of Rochester Medical Center, Rochester, New York, USA.

Himabindu Vidula (H)

Department of Medicine (Cardiology), University of Rochester Medical Center, Rochester, New York, USA.

Samit Shah (S)

Department of Medicine (Cardiology), NorthWell Health, Manhasset, New York, USA.

Scott Feitell (S)

Department of Medicine (Cardiology), Rochester Regional Medical Center, Bronx, New York, USA.

Kristi S Masser (KS)

Abbott Inc., Abbott Park, Illinois, USA.

Arman Kilic (A)

Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.

Danyaal Moin (D)

Department of Medicine (Cardiology), Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA.

Pavan Atluri (P)

Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Edo Barati (E)

Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH